Keyword: Protein Sciences
Not long after its acquisition by Sanofi, Protein Sciences is bidding adieu to its former leader.
Here's some other vaccine news of note for the week.
Egg-based production dampened the effects of last year's flu vaccine, a new study says. What's worse, the problem could repeat this year.
Here's other vaccine news of note for this week.
It's summer, when few are thinking about the coming influenza threat. But top vaccine makers are already kicking off their flu shot shipments.
Though not nearly on the scale of Sanofi's runs at Medivation or Actelion, the Protein Sciences buyout promises a boost for its flu vaccines lineup.
The U.S. could run into a vaccine supply predicament if an influenza pandemic hits, since only one drugmaker has a domestic facility with egg-based vaccine production capabilities.
Argentina's Sinergium Biotech, which is in a consortium to develop a Zika virus vaccine, intends to build a new plant that will use cell biology that can be utilized for a Zika vaccine or for the flu vaccine production it already does.
Protein Sciences will start the search for two new H7N9 vaccine candidates by request of the HHS’ Biomedical Advanced Research and Development Authority.
Astellas pulled the plug on a cell culture flu vaccine partnership with UMN Pharma after Japanese regulators stiff-armed its application for approval.